Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Steris (NYSE: STE ) �-- a manufacturer of infection prevention, contamination control, and surgical support products for the health-care industry -- jumped as much as 10% after reporting better-than-expected fourth-quarter results.
So what: For the quarter, Steris' shareholders witnessed revenue increase by 10% to $428.2 million as EPS shrank modestly to $0.70 from $0.76 in the year-ago period. Although Steris blamed European weakness and the medical device excise tax for its weaker bottom-line results, both figures topped the $406 million in revenue and $0.65 in EPS that the Street had been expecting. The biggest boost came from the company's life sciences segment, which saw operating income grow by 14%. For the upcoming year, Steris issued guidance calling for revenue growth of 8%-10% (implying $1.62 billion to $1.65 billion) and EPS of $2.47-$2.60. Current consensus estimates are for revenue of $1.57 billion and EPS of $2.49.
Top Dow Dividend Companies For 2015: Monarch Casino & Resort Inc (MCRI)
Monarch Casino & Resort, Inc. (Monarch), incorporated in 1993, through its wholly owned subsidiary, Golden Road Motor Inn, Inc. (Golden Road), owns and operates the Atlantis Casino Resort Spa(the Atlantis), a hotel/casino facility in Reno, Nevada. Monarch�� other wholly owned subsidiaries, High Desert Sunshine, Inc. (High Desert) and Golden North, Inc. (Golden North), each own separate parcels of land located adjacent to the Atlantis. The Company owns and operates the Atlantis Casino Resort Spa, which is located approximately three miles south of downtown in the area of Reno, Nevada. The Atlantis features approximately 61,000 square feet of casino space; a hotel with 824 guest rooms and suites; ten food outlets; an enclosed year-round pool with waterfall; an outdoor pool; a health spa; two retail outlets offering clothing and resort gift shop merchandise; a full service salon for men and women; an 8,000 square-foot family entertainment center; and approximately 52,000 square feet of banquet, convention and meeting room space. During the year ended December 31, 2011, the Company acquired 1.5 acre parcel of developable land contiguous to the Riviera Black Hawk Casino.
In April 2012, it acquired Riviera Black Hawk, Inc.
The Atlantis Casino offers approximately 1,450 slot and video poker machines; approximately 39 table games, including blackjack, craps, roulette and others; a race and sports book; keno and a poker room. The Atlantis includes three contiguous high-rise hotel towers with 824 rooms and suites. The Atlantis includes three contiguous high-rise hotel towers with a total of 824 rooms and suites. The first of the three hotel towers contains 160 rooms and suites in 13 stories. The 19-story second hotel tower contains 278 rooms and suites. The third tower contains 386 rooms and suites in 28 stories.
The Atlantis hotel rooms feature designs and furnishings consistent with the Northern Nevada market, as well as nine-foot ceilings (most standard hotel rooms have eig! ht-foot ceilings), which create an open and spacious feel. The third hotel tower features a four-story waterfall with an adjacent year-round swimming pool in a climate controlled, five-story glass enclosure, which shares an outdoor third floor pool deck with a seasonal outdoor swimming pool and year round whirlpool. A full-service salon (the Salon at Atlantis) overlooks the third floor sundeck and outdoor seasonal swimming pool and offers salon-grade products and treatments for hair, nails, skincare and body services for both men and women. A health spa is located adjacent to the swimming areas, which offers treatments and amenities. The hotel rooms on the spa floor are designated as spa rooms and feature decor that is themed consistent with the spa. Certain spa treatments are also available in spa floor hotel rooms. The hotel also features glass elevators rising the full 19 and 28 stories, of the respective towers providing views of the Reno area and the Sierra Nevada mountain range.
The Atlantis has eight restaurants, two gourmet coffee bars and one snack bar. It includes 160-seat Atlantis Steakhouse gourmet restaurant; the 200-seat upscale Bistro Napa featuring a centrally located wine cellar; the Oyster Bar restaurant in the Sky Terrace offering fresh seafood, soups and bisques made to order; the Sushi Bar, also in the Sky Terrace, offering a variety of fresh raw and cooked sushi specialties, including all-you-can-eat lunch and dinner selections. The Oyster Bar and Sushi Bar can accommodate up to 139 guests; The 178-seat 24-hour Purple Parrot coffee shop; the 122-seat Cafe Alfresco restaurant serving a full menu, pizzas prepared in a wood-fired, brick oven and a variety of gelato deserts; the 170-seat Manhattan Deli restaurant specializing in piled-high sandwiches, soups, salads and desserts; two gourmet coffee bars, offering specialty coffee drinks, pastries and desserts made fresh daily in the Atlantis bakery; a snack bar and soda fountain serving ice cream and arcade-style refreshmen! ts.
The Sky Terrace is a structure with a diamond-shaped, blue glass body suspended approximately 55 feet, and spanning 160 feet across, South Virginia Street. The Sky Terrace connects the Atlantis with additional parking on its 16-acre site across South Virginia Street from the Atlantis. The structure rests at each end on two 100-foot tall Grecian columns with no intermediate support pillars. The interior of the Sky Terrace contains the Oyster Bar, the Sushi Bar, a video poker bar, banks of slot machines and a lounge area with oversized leather sofas and chairs.
Advisors' Opinion:- [By Vanina Egea] ong>Risks and Valuation
Although the Chinese government will maintain its gambling restrictions in the mainland over the next decade, Sand Corp�� market share and leverage in fixed costs will continue to riel in strong revenue growth from this region. Fiscal 2013 marked a 24.80% revenue increase ($13.8 billion) and operating margins continue to expand at the same pace. Despite the inherent risk of an economic slowdown in Asia or a recession in the U.S., which could put a halt to leisure spending, the company is well prepared to balance out any short-term losses. The casino operator�� EBITDA growth of 65.30%, for example, is an impressive result when compared to the industry�� average of 4.90%.
Looking forward, earnings per share are expected to continue their fast-paced upward trend, having jumped from $1.56 in 2011 to $2.79 at the end of fiscal 2013. The 21.6% return on equity, as well as 1.80% dividend yield should also be attractive to shareholders and future investors. Although Las Vegas Sand Corp is currently trading at a 24% price premium relative to the industry average of 22.60x trailing earnings, I feel very bullish about this firm�� long term profitability, given its strong market position in Asia.
Disclosure: Vanina Egea holds no position in any stocks mentioned.
Also check out: Andreas Halvorsen Undervalued Stocks Andreas Halvorsen Top Growth Companies Andreas Halvorsen High Yield stocks, and Stocks that Andreas Halvorsen keeps buying
About the author:Vanina EgeaA fundamental analyst at Lone Tree AnalyticsVisit Vanina Egea's Website
Hot Life Sciences Stocks To Watch Right Now: IGI Laboratories Inc. (IG)
IGI Laboratories, Inc. engages in developing, manufacturing, filling, and packaging topical semi-solid and liquid products for cosmetic, cosmeceutical, and pharmaceutical customers in the United States. The company�s products are used for various skin conditions, including the treatment of symptoms of dermatitis, acne, psoriasis, and eczema. It offers contract formulation and contract manufacturing services to a range of topical formulations, including creams, ointments, lotions, gels, and topical liquids. The company is also developing a portfolio of prescription generic formulations in topical dosage forms. IGI Laboratories, Inc., through its license agreement with Novavax, Inc., utilizes the Novasome lipid vesicle encapsulation and certain other technologies for applications in animal pharmaceuticals, biologicals, and other animal health products; foods, food applications, nutrients, and flavorings; cosmetics, consumer products, and dermatological over-the-counter and prescription products; fragrances; and chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals, and other specialty chemicals. The company was formerly known as IGI, Inc. and changed its name to IGI Laboratories, Inc. in May 2008. IGI Laboratories, Inc. was founded in 1977 and is based in Buena, New Jersey.
Advisors' Opinion:- [By Holly LaFon]
The Barclays Aggregate Index rose by 0.57% in 3Q13, having stood at a loss of -0.36% the day before the FOMC's declaration to not slow QE. Despite the bounce, the Index remains in negative territory YTD and for the trailing 12-months at -1.77% and -1.68%, respectively. In stark contrast to 2Q13, Investment Grade (IG) corporate spreads tightened 10bps during 3Q13, producing a positive nominal return of 0.82% and an excess return of 0.92%. The respective YTD total returns in IG remain a disappointing -2.62%, but excess returns are still positive at 0.61% YTD. The 1-Yr results for IG Credit now fall to a nominal -1.58%, but 1.79% in excess of Treasuries.
Hot Life Sciences Stocks To Watch Right Now: China Sunergy Co. Ltd.(CSUN)
China Sunergy Co., Ltd. designs, develops, manufactures, and sells solar cells and solar modules. It offers monocrystalline and multicrystalline silicon solar cells; and standard P-type solar cells and HP solar cells, as well as emitter cells. The company sells its products to module manufacturers, system integrators, and distributors. It sells solar cells and modules under CSUN and CEEG brand names primarily in Europe, the People?s Republic of China, India, South Korea, Australia, and the Untied States. The company was founded in 2004 and is headquartered in Nanjing, the People?s Republic of China.
Advisors' Opinion:- [By Eric Volkman]
China Sunergy (NASDAQ: CSUN ) results for the company's fiscal Q4 and 2012 have been released. For the quarter, total sales were $54.4 million, less than half the $110.8 million the firm posted in the same period the previous year. Net loss, meanwhile, was steeper at $70.5 million ($5.27 per diluted American Depositary Share), compared to Q4 2011's red figure of $49.6 million ($3.71).
Hot Life Sciences Stocks To Watch Right Now: Maxwell Technologies Inc.(MXWL)
Maxwell Technologies, Inc., together with its subsidiaries, develops, manufactures, and markets energy storage and power delivery products, and microelectronic products worldwide. The company offers Ultracapacitors that are energy storage devices to provide energy storage and power delivery solutions for applications in transportation, automotive, information technology, renewable energy, and industrial electronics industries; and CONDIS high-voltage capacitors comprising grading and coupling capacitors, and capacitive voltage dividers used to ensure the safety and reliability of electric utility infrastructure and other applications involving transport, distribution, and measurement of high-voltage electrical energy. It also provides radiation-hardened microelectronic products, including single board computers and components, such as high-density memory and power modules for satellites and spacecraft applications. The company markets and sells its products through direct and indirect sales for integration by original equipment manufacturers into a range of end products. The company was formerly known as Maxwell Laboratories, Inc. and changed its name to Maxwell Technologies, Inc. in 1996. Maxwell Technologies was founded in 1965 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Roberto Pedone]
Maxwell Technologies (MXWL) develops, manufactures and markets energy storage and power delivery products for transportation, industrial telecommunications and other applications and microelectronic products for space and satellite applications. This stock closed up 3.7% to $9.50 in Tuesday's trading session.
Tuesday's Range: $9.07-$9.54
52-Week Range: $4.90-$11.08
Tuesday's Volume: 369,000
Three-Month Average Volume: 360,477From a technical perspective, MXWL spiked notably higher here right above some near-term support at $9 with above-average volume. This stock has been consolidating and trending sideways for the last two months, with shares moving between $8.61 on the downside and $10.39 on the upside. Shares of MXWL are now quickly moving within range of triggering a near-term breakout trade above the upper-end of its recent sideways trading chart pattern. That trade will hit if MXWL manages to take out Tuesday' high of $9.54 and then once it clears more near-term overhead resistance at $10.39 with high volume.
Traders should now look for long-biased trades in MXWL as long as it's trending above its 50-day at $8.81 and then once it sustains a move or close above those breakout levels with volume that's near or above 360,477 shares. If that breakout hits soon, then MXWL will set up to re-test or possibly take out its 52-week high at $11.08. Any high-volume move above that level will then give MXWL a chance to tag $12.
- [By Monica Gerson]
Maxwell Technologies (NASDAQ: MXWL) surged 9.20% to $10.21. The volume of Maxwell Technologies shares traded was 325% higher than normal. Maxwell's trailing-twelve-month revenue is $190.57 million.
Hot Life Sciences Stocks To Watch Right Now: Enanta Pharmaceuticals Inc (ENTA)
Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The Company is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes-protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase, as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. ABT-450, discovered through its collaboration with AbbVie, is a protease inhibitor that has demonstrated in vitro potency against known resistant HCV mutants.
In Phase I studies, ABT-450 co-administered with ritonavir, a commonly used boosting agent to increase the blood concentrations of many protease inhibitors, was shown to be safe and well tolerated. Co-administration of ABT-450 with ritonavir, which it refers to together as ABT-450/r, has enabled once-daily dosing of ABT-450. Phase II studies have demonstrated the efficacy of ABT-450/r in patients with chronic HCV, and other interferon-free Phase II studies of ABT-450-containing regimens continue. AbbVie is developing a next-generation protease inhibitor discovered within the Enanta-AbbVie collaboration. EDP-239 is the NS5A inhibitor discovered by the Company. The Company also has a program to develop nucleotide inhibitors to HCV NS5B polymerase, which is another DAA mechanism considered to have a barrier to resistance. The Company�� Bicyclolide antibiotic product candidate is EDP-788, which it is developing for use as an intravenous drug in the hospital setting and for oral dosing in the home setting. EDP-788 is a prodrug, which means that it is inactive until it is converted in the body into an active compound. EDP-788 is! a water-soluble molecule which, when administered in preclinical models, is cleanly and rapidly converted into the active compound.
Advisors' Opinion:- [By George Budwell]
Normally, such strong efficacy results would be hailed as a major achievement. However, these results are actually less impressive than those by competing drug's developed by AbbVie (NYSE: ABBV ) , Enanta Pharmaceuticals (NASDAQ: ENTA ) and Gilead. Bristol-Myers' therapy also has a treatment duration double that of Gilead's drug Sovaldi for genotype 1 patients. So, while these results are impressive in their own right, the therapy's commercial prospects may be limited due to the presence of superior competitors in the market.�
- [By Sean Williams]
The next big thing in treating hepatitis-C
The other currently experimental therapy very likely to make it onto the FDA's desk before the midpoint of 2014 is AbbVie's (NYSE: ABBV ) direct-acting antiviral combo drug. In similar fashion to Sovaldi, this DAA-combo therapy, which includes ABT-450 from Enanta Pharmaceuticals (NASDAQ: ENTA ) , is running six confirmatory late-stage trials on various genotypes. There are, however, two primary differences between AbbVie's DAA-combo therapy and Sovaldi. - [By James Fink]
And lastly I'll go into healthcare, which is kind of a growth cyclical type name. It's partially defensive, partially growth. I think the more growth-oriented section of healthcare would be biotech, and right now, a very promising biotech stock is Enanta Pharmaceuticals. That's a NASDAQ stock; ticker symbol (ENTA).
Hot Life Sciences Stocks To Watch Right Now: HealthStream Inc (HSTM)
HealthStream, Inc. (HealthStream), incorporated in September 27, 1990, provides Internet-based learning and research solutions for healthcare organizations. The Company�� learning products are used by healthcare organizations to meet a range of their training, certification, and development needs, while its research products provide the customers information about patients��experiences, workforce engagement, physician relations, and community perceptions of their services. HealthStream�� products and services are organized into two segments: HealthStream Learning and HealthStream Research. HealthStream�� customers include healthcare organizations, pharmaceutical and medical device companies, and other participants in the healthcare industry. Its customer base across both learning and research business units includes over 3,000 healthcare organizations (predominately acute-care facilities) throughout all 50 states of the United States. In March 2014, the Company acquired Health Care Compliance Strategies, Inc., a Jericho, New York-based company focused on interactive and engaging online compliance training for healthcare organizations.
The Company�� core learning product is the HealthStream Learning Center (HLC), its learning platform provided through the Internet through software-as-a-service (SaaS) model. As of December 31, 2012, HealthStream had approximately 3.1 million contracted, primarily hospital-based subscribers, to the HLC platform. It delivers educational and training courseware to its customers through the HLC platform. Its research products and service offerings include satisfaction surveys, data analyses of survey results, and other research-based measurement tools focused on patients, physicians, employees, and members of the community. The Company�� core research product is the Patient Insights survey.
HealthStream Learning & Talent Management
Within HealthStream Learning & Talent Management, the Company brings training, assessment and! education content together with administrative and management tools through its HLC , HCC, and HPC. It also offers a more streamlined version of the HLC, HealthStream Express, along with HealthStream Connect, a content delivery platform that is designed for the singular purpose of allowing access to its content libraries. These content libraries allow HLC platform customers to subscribe to an array of additional courseware. Additionally, through its Hospital Direct capability in the HLC, medical device companies can offer online training support for their products and sponsor continuing education directly to healthcare workers.
The Company�� learning management system supports healthcare administrators in configuring training to meet the needs of various groups of employees, modifying training materials, and documenting training completion. It offer training, implementation, and account management services to facilitate adoption of its platform. Offered via a SaaS model, its Internet-based platform and its courseware are hosted in a central data center that allows authorized subscribers Internet access to its services.
In addition to the HLC, the Company offers an array of platform extensions, each serving a function for hospitals and health systems. The Authoring Center is a platform extension that provides healthcare organizations the capability to create Internet-based courses by moving their existing course material online or self-authoring new material and electively sharing these materials with its other customers through a courseware exchange. It also offers Authoring Pro, an upgraded product, which includes a licensed image library, as an additional subscription to this product. The HealthStream Competency Center (HCC) is its SaaS-based platform extension for competency management solution for healthcare organizations, provides customers tools to assess competency and appraise performance.
SimCenter, the Company�� platform extension offer products and ! services ! focused on accelerating the global adoption of simulation-based learning by healthcare providers with a focus on improving clinical competencies and patient outcomes. The new venture offers healthcare organizations and medical and nursing schools worldwide a range of integrated SaaS applications that accelerate development and distribution of simulation content; enable enterprise-wide management of simulation centers, simulators, and programs, and support assessment of the effectiveness of simulation training as part of complete curricula.
The HealthStream Improvement Center is a SaaS-based platform extension related to its research offering. This extension is an online system for hospital leaders to optimize and accelerate the execution of improvement plans, including those based on results from its patient, employee, physician, and community surveys. The Improvement Center, a licensed technology, is one of a number of solutions from HealthStream Research that include a line of survey products, national benchmarks, HCAHPS Improvement Library, consulting services, and other support tools.
HealthStream Research
HealthStream Research complements HealthStream Learning�� product and service offerings by providing hospital-based customers with Patient Insights, Employee Insights, Physician Insights, and Community Insights surveys, data analyses of survey results, and other research-based measurement tools. Its services are designed to provide thorough analyses that provide insightful recommendations for change; benchmarking capability using its databases, and consulting services to identify solutions for its customers based on their survey results. Its survey and research solutions focus on providing valid data to assist its customers. In addition to collecting and reporting data, the Company provides analysis and consulting to help customers understand their survey results and the underlying impact on their business. It is with this insight that healthcare organizati! ons are a! ble to develop plans for improved performance that can be delivered through its learning solutions.
The Company competes with Cornerstone OnDemand, Healthcare Source, Oracle, SABA, SAP, SumTotal Systems, Avatar International, Gallup, National Research Corporation, Press Ganey Associates, Professional Research Consultants, Inc., Kenexa, Foresight, B-Line Medical, CAE/Meti, and EMS
Advisors' Opinion:- [By Jake L'Ecuyer]
Healthstream (NASDAQ: HSTM) was down, falling 4.28 percent to $25.94 after Northland Securities downgraded the stock from Outperform to Market Perform and lowered the target price from $43 to $30.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Healthstream (Nasdaq: HSTM ) , whose recent revenue and earnings are plotted below. - [By Jake L'Ecuyer]
Healthstream (NASDAQ: HSTM) was down, falling 4.28 percent to $25.94 after Northland Securities downgraded the stock from Outperform to Market Perform and lowered the target price from $43 to $30.
Hot Life Sciences Stocks To Watch Right Now: PAREXEL International Corporation(PRXL)
PAREXEL International Corporation, a biopharmaceutical services company, provides a range of clinical research, medical communications, consulting, commercialization, and technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics (Perceptive). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, and clinical pharmacology, as well as related medical advisory, patient recruitment, and investigator site services. This segment also manages various aspects of clinical trials, including study and protocol design; case report form design; paper or electronic questionnaires designed for use in clinical research; site and investigator recruitment; patient enrollment; study monitoring and data collection; data analysis; report writing; and medical services. The PCMS segment provides technical expertise and advice in various areas comprising drug development, regulatory affairs, product pricing and reimbursement, and GMP compliance; market development, product development, and targeted communications services in support of product launch. In addition, its consultants identify alternatives and propose solutions to address clients? product development, registration, and commercialization issues. The Perceptive segment provides information technology solutions comprising medical imaging and systems integration services; ClinPhone RTSM, CTMS, and EDC products; Web-based portals; systems integration; and patient diary applications. PAREXEL International Corporation was founded in 1983 and is headquartered in Waltham, Massachusetts.
Advisors' Opinion:- [By Eric Volkman]
PAREXEL (NASDAQ: PRXL ) has purchased a complementary asset. The company announced it bought the entirety of HERON Group, a life sciences consultancy that according to PAREXEL "provides evidence-based commercialization services to support biopharmaceutical companies throughout the lifecycle of their products."
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on PAREXEL International (Nasdaq: PRXL ) , whose recent revenue and earnings are plotted below.
No comments:
Post a Comment